Results 191 to 200 of about 2,555,654 (307)

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

When priapism reveals Chronic Myeloid Leukemia: A case report. [PDF]

Urol Case Rep
Afif Syamhudi MF, Nitisasmito AP, Setiawan EI.   +2 more
europepmc   +1 more source

Chronic myeloid leukemia in India

Indian Journal of Medical and Paediatric Oncology, 2013
openaire   +3 more sources

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis. [PDF]

Cancer Chemother Pharmacol
Abumiya M, Abe K, Watanabe A, Takahashi N.   +3 more
europepmc   +1 more source

Nutrimental Determinants of Chronological Aging and Competitiveness in the snf1Δ Warburg Model

Yeast, EarlyView.
Deletion of SNF1 in Saccharomyces cerevisiae alters chronological aging in a nutrient‐dependent manner, shortening lifespan under low‐nutrient conditions and extending it under high‐glucose and high‐amino‐acid conditions. Under nutrient‐rich conditions, the snf1∆ strain also showed an approximately 2‐log increase in competitiveness relative to the wild
Abigail Correa‐Olivares, Amanda de la Caridad Lahera Champagne, Alma Delia Bertadillo‐Jilote, Karla I. Lira‐de Leon, David G. Garcia‐Gutierrez, Gerardo M. Nava, Vanessa Sanchez‐Quezada, Luis Alberto Madrigal‐Perez   +7 more
wiley   +1 more source

Therapeutic challenges in the management of chronic myeloid leukemia during pregnancy: A report of two cases. [PDF]

Case Rep Womens Health
Chiquillo MA, Mendoza RLA, Emiliani JF, Rangel VS, Bazurto MPV, Benítez MLS.   +5 more
europepmc   +1 more source

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

Bone Marrow Aplasia Under Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Rare and Unpredictable Complication. [PDF]

Cureus
Annasser M, Halloumi O, Fatima Ezzahra R, Fares S.   +3 more
europepmc   +1 more source

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija, Fiona Kerr, Hazel Gough, Johnathan Soggee, Laurence C. Cheung, Rishi S. Kotecha, Shanti Ramachandran   +6 more
wiley   +1 more source